评估muvalaplin用于降低脂蛋白的临床进展 (一)
Amanda J Hooper1,2, P Mihika S Fernando3, John R Burnett1,2
1Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital & Fiona Stanley Hospital Network, Perth, WA, Australia.
Expert opinion on investigational drugs
|November 10, 2025
概括
口服药物穆瓦拉普林在高风险患者中显著降低了脂蛋白[Lp]水平,高达70%. 这一发展为动脉样硬化心血管疾病 (ASCVD) 风险与升高的Lp (a) 相关的有前途的新疗法提供了希望.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 脂质代谢 脂质代谢是什么
背景情况:
- 升高的脂蛋白 (Lp) 是动脉样硬化心血管疾病 (ASCVD) 的重要危险因素.
- 目前用于降低Lp (a) 的治疗策略有限,几乎没有药理选择.
- 针对Lp(a) 形成的新疗法正在开发中,以减轻ASCVD风险.
研究的目的:
- 为了评估口服Lp(a) 抑制剂muvalaplin的疗效和安全性.
- 评估穆瓦拉普林对高心血管风险的成年人Lp (a) 水平的影响.
- 探索口服穆瓦拉普林的潜力,作为一个方便的治疗升高的Lp.
主要方法:
- 这项研究涉及高心血管风险和升高Lp的成年人.
- 参与者接受了口服小分子抑制剂Muvalaplin的治疗.
- 使用传统和新型异形不敏感测定方法测量了Lp (a) 水平.
主要成果:
- 穆瓦拉普林显著降低了Lp (a) 水平,高危患者的水平高达70%和85.5%.
- 安全性和耐受性概况是有希望的,对等离子体活性的影响最小.
- 与注射疗法相比,口服穆瓦拉普林在患者的方便性和坚持性方面可能具有优势.
结论:
- 穆瓦拉普林是第一个口服小分子抑制剂,可以减少Lp (a) 形成.
- 在高危人群中,该药物显著降低了Lp(a),这表明潜在的新ASCVD治疗方法.
- 需要在III期试验中进行进一步的调查,以确认心血管结果.
更多相关视频
03:42Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
2.0K
11:13Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate
Published on: May 9, 2019
9.2K
相关概念视频
01:26Atherosclerosis III: Management
307
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
307
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:24Lipid Absorption
2.4K
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
2.4K